Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07110844 · ClinicalTrials.gov registry record · Phase 2
Teclistamab-Daratumumab in AL Amyloidosis
A Phase 2 study of Amyloid Light-chain Amyloidosis, sponsored by Suzanne Lentzsch, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT07110844: Recruiting Phase 2 study of Amyloid Light-chain Amyloidosis, sponsored by Suzanne Lentzsch, MD.
NCT07110844 is a Phase 2 study of Amyloid Light-chain Amyloidosis that is actively recruiting participants, run by Suzanne Lentzsch, MD. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07110844, a Phase 2 study of Amyloid Light-chain Amyloidosis, is actively recruiting participants, sponsored by Suzanne Lentzsch, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Primary Outcome
Heme-CR will be defined as: involved free light-chain level less than the upper limit of the normal range with negative serum and urine immunofixation; normalization of the uninvolved free light-chain level or free light-chain ratio will not be required to determine a complete response.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Daratumumab and Hyaluronidase-fihj
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-11-07 |
| Est. Completion | 2033-10 |
| Phase | Phase 2 |
What NCT07110844 shows while recruiting
NCT07110844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Amyloid Light-chain Amyloidosis appearing as the primary indexed condition, and to 2 interventions - of which Teclistamab is the first listed.
NCT07110844 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07110844 about?
NCT07110844 is a clinical study titled "Teclistamab-Daratumumab in AL Amyloidosis". The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
What is the current status of trial NCT07110844?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-11-07. Estimated completion is 2033-10.
What conditions does trial NCT07110844 study?
This clinical trial studies the following conditions: Amyloid Light-chain Amyloidosis.
What interventions are being tested in trial NCT07110844?
The interventions under investigation include: Teclistamab (DRUG), Daratumumab and Hyaluronidase-fihj (DRUG).
Who is sponsoring clinical trial NCT07110844?
This trial is sponsored by Suzanne Lentzsch, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07110844 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07110844's enrollment target sits among peer trials
25 1719th of 2000 higher than 246 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI